Freeline Therapeutics Holdings PLC ADR (FRLN) News
Filter FRLN News Items
FRLN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest FRLN News From Around the Web
Below are the latest news stories about FREELINE THERAPEUTICS HOLDINGS PLC that investors may wish to consider to help them evaluate FRLN as an investment opportunity.
Freeline (FRLN) Shares Rise on Merger Agreement With SynconaFreeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise. |
Syncona to Acquire Freeline TherapeuticsFreeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline’s independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline’s near-term capital needs and support ongoing adva |
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual CongressSubstantial reduction in lyso-Gb1 substrate levels, an established biomarker of clinical response, observed in first patient treated with FLT201 Increases of several hundredfold over baseline in plasma GCase activity and normalization of cellular GCase levels continue to be observed in first two patients treated with FLT201 FLT201 continues to be well-tolerated, with no serious adverse events Third patient dosed this month in ongoing Phase 1/2 GALILEO-1 trial LONDON, Oct. 25, 2023 (GLOBE NEWSWIR |
Here's Why We're A Bit Worried About Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn SituationWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual CongressLONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will present new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate, in patients with Gaucher disease Type 1 at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress being held October 24-27, 2023 in Brussels, Belgium. The oral presentation will include data on safety, tolerability, GCase en |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday. |
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher DiseaseRobust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events Company to host conference call today at 8 a.m. ET LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported positive initial safety, tolerability and enzyme activity data fr |
Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Q2 2023 Earnings Call TranscriptFreeline Therapeutics Holdings plc (NASDAQ:FRLN) Q2 2023 Earnings Call Transcript August 15, 2023 Freeline Therapeutics Holdings plc misses on earnings expectations. Reported EPS is $-4.16 EPS, expectations were $3.62. Operator: Good morning, everyone, and welcome to the Freeline Second Quarter 2023 Financial and Business Update Conference Call. All participants will be in a listen-only mode. […] |
Q2 2023 Freeline Therapeutics Holdings PLC Earnings CallQ2 2023 Freeline Therapeutics Holdings PLC Earnings Call |
Freeline Reports Second Quarter 2023 Financial Results and Business HighlightsCompleted dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson’s disease Management to host conference call at 8:00 a.m. ET today LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today reported financial results for the second quarter of 2023 and provided a business updat |